Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atomoxetine + eszopiclone
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of atomoxetine, a selective norepinephrine reuptake inhibitor, and eszopiclone, a sedative-hypnotic medication. This combination has been studied for the treatment of obstructive sleep apnea (OSA). Atomoxetine increases upper airway muscle activity by enhancing noradrenergic signaling, while eszopiclone helps maintain sleep quality and increases the respiratory arousal threshold. The combination aims to reduce OSA severity by targeting multiple underlying mechanisms.
02
Targets
NET (Norepinephrine Transporter)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on atomoxetine + eszopiclone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atomoxetine + eszopiclone.